We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Extension of Comment Period On Amending ANDA, 505(b)(2)
Extension of Comment Period On Amending ANDA, 505(b)(2)
In response to overwhelming requests from industry, the FDA is extending to June 8 the comment period on its draft rule overhauling the ANDA and 505(b)(2) approval processes.